153 related articles for article (PubMed ID: 21951562)
1. mRNA expression levels and genetic status of genes involved in the EGFR and NF-κB pathways in metastatic non-small-cell lung cancer patients.
Santarpia M; Magri I; Sanchez-Ronco M; Costa C; Molina-Vila MA; Gimenez-Capitan A; Bertran-Alamillo J; Mayo C; Benlloch S; Viteri S; Gasco A; Mederos N; Carcereny E; Taron M; Rosell R
J Transl Med; 2011 Sep; 9():163. PubMed ID: 21951562
[TBL] [Abstract][Full Text] [Related]
2. BRCA1, LMO4, and CtIP mRNA expression in erlotinib-treated non-small-cell lung cancer patients with EGFR mutations.
Karachaliou N; Costa C; Gimenez-Capitan A; Molina-Vila MA; Bertran-Alamillo J; Mayo C; Massuti B; Majem M; Carcereny E; Moran T; Sanchez JJ; Viteri S; Gasco A; Wannesson L; Souglakos J; Jimeno J; Rosell R;
J Thorac Oncol; 2013 Mar; 8(3):295-300. PubMed ID: 23407556
[TBL] [Abstract][Full Text] [Related]
3. Customized treatment in non-small-cell lung cancer based on EGFR mutations and BRCA1 mRNA expression.
Rosell R; Perez-Roca L; Sanchez JJ; Cobo M; Moran T; Chaib I; Provencio M; Domine M; Sala MA; Jimenez U; Diz P; Barneto I; Macias JA; de Las Peñas R; Catot S; Isla D; Sanchez JM; Ibeas R; Lopez-Vivanco G; Oramas J; Mendez P; Reguart N; Blanco R; Taron M
PLoS One; 2009; 4(5):e5133. PubMed ID: 19415121
[TBL] [Abstract][Full Text] [Related]
4. Pretreatment EGFR T790M mutation and BRCA1 mRNA expression in erlotinib-treated advanced non-small-cell lung cancer patients with EGFR mutations.
Rosell R; Molina MA; Costa C; Simonetti S; Gimenez-Capitan A; Bertran-Alamillo J; Mayo C; Moran T; Mendez P; Cardenal F; Isla D; Provencio M; Cobo M; Insa A; Garcia-Campelo R; Reguart N; Majem M; Viteri S; Carcereny E; Porta R; Massuti B; Queralt C; de Aguirre I; Sanchez JM; Sanchez-Ronco M; Mate JL; Ariza A; Benlloch S; Sanchez JJ; Bivona TG; Sawyers CL; Taron M
Clin Cancer Res; 2011 Mar; 17(5):1160-8. PubMed ID: 21233402
[TBL] [Abstract][Full Text] [Related]
5. Combined analysis of rearrangement of ALK, ROS1, somatic mutation of EGFR, KRAS, BRAF, PIK3CA, and mRNA expression of ERCC1, TYMS, RRM1, TUBB3, EGFR in patients with non-small cell lung cancer and their clinical significance.
Zhang Q; Sun T; Kang P; Qian K; Deng B; Zhou J; Wang R; Jiang B; Li K; Liu F; Wu S; Tan Q
Cancer Chemother Pharmacol; 2016 Mar; 77(3):583-93. PubMed ID: 26842788
[TBL] [Abstract][Full Text] [Related]
6. ERCC1 and BRAC1 mRNA expression levels in the primary tumor could predict the effectiveness of the second-line cisplatin-based chemotherapy in pretreated patients with metastatic non-small cell lung cancer.
Papadaki C; Sfakianaki M; Ioannidis G; Lagoudaki E; Trypaki M; Tryfonidis K; Mavroudis D; Stathopoulos E; Georgoulias V; Souglakos J
J Thorac Oncol; 2012 Apr; 7(4):663-71. PubMed ID: 22425915
[TBL] [Abstract][Full Text] [Related]
7. XPG mRNA expression levels modulate prognosis in resected non-small-cell lung cancer in conjunction with BRCA1 and ERCC1 expression.
Bartolucci R; Wei J; Sanchez JJ; Perez-Roca L; Chaib I; Puma F; Farabi R; Mendez P; Roila F; Okamoto T; Taron M; Rosell R
Clin Lung Cancer; 2009 Jan; 10(1):47-52. PubMed ID: 19289372
[TBL] [Abstract][Full Text] [Related]
8. Over-expression of AEG-1 significantly associates with tumour aggressiveness and poor prognosis in human non-small cell lung cancer.
Song L; Li W; Zhang H; Liao W; Dai T; Yu C; Ding X; Zhang L; Li J
J Pathol; 2009 Nov; 219(3):317-26. PubMed ID: 19644957
[TBL] [Abstract][Full Text] [Related]
9. FAS and NF-κB signalling modulate dependence of lung cancers on mutant EGFR.
Bivona TG; Hieronymus H; Parker J; Chang K; Taron M; Rosell R; Moonsamy P; Dahlman K; Miller VA; Costa C; Hannon G; Sawyers CL
Nature; 2011 Mar; 471(7339):523-6. PubMed ID: 21430781
[TBL] [Abstract][Full Text] [Related]
10. AEG-1 mRNA expression in non-small cell lung cancer is associated with increased tumor angiogenesis.
Ma Z; Chen Y; Dong S; Xu X; Liu J; Song P; Yu C; Dai L
Pathol Res Pract; 2017 Oct; 213(10):1257-1263. PubMed ID: 28941723
[TBL] [Abstract][Full Text] [Related]
11. Erlotinib for Patients with EGFR Wild-Type Metastatic NSCLC: a Retrospective Biomarkers Analysis.
Inno A; Di Noia V; Martini M; D'Argento E; Di Salvatore M; Arena V; Schinzari G; Orlandi A; Larocca LM; Cassano A; Barone C
Pathol Oncol Res; 2019 Apr; 25(2):513-520. PubMed ID: 29557085
[TBL] [Abstract][Full Text] [Related]
12. Expression of DNA repair and replication genes in non-small cell lung cancer (NSCLC): a role for thymidylate synthetase (TYMS).
Kotoula V; Krikelis D; Karavasilis V; Koletsa T; Eleftheraki AG; Televantou D; Christodoulou C; Dimoudis S; Korantzis I; Pectasides D; Syrigos KN; Kosmidis PA; Fountzilas G
BMC Cancer; 2012 Aug; 12():342. PubMed ID: 22866924
[TBL] [Abstract][Full Text] [Related]
13. Differential expression of RBM5, EGFR and KRAS mRNA and protein in non-small cell lung cancer tissues.
Liang H; Zhang J; Shao C; Zhao L; Xu W; Sutherland LC; Wang K
J Exp Clin Cancer Res; 2012 Apr; 31(1):36. PubMed ID: 22537942
[TBL] [Abstract][Full Text] [Related]
14. Poor response to platinum-based chemotherapy is associated with KRAS mutation and concomitant low expression of BRAC1 and TYMS in NSCLC.
Zhou H; Dai Y; Zhu L; Wang C; Fei X; Pan Q; Chen J; Shi X; Yang Y; Tao X; Shi P
J Int Med Res; 2016 Feb; 44(1):89-98. PubMed ID: 26740498
[TBL] [Abstract][Full Text] [Related]
15. Hypoxia-inducible factor-1α and nuclear factor-κB play important roles in regulating programmed cell death ligand 1 expression by epidermal growth factor receptor mutants in non-small-cell lung cancer cells.
Guo R; Li Y; Wang Z; Bai H; Duan J; Wang S; Wang L; Wang J
Cancer Sci; 2019 May; 110(5):1665-1675. PubMed ID: 30844110
[TBL] [Abstract][Full Text] [Related]
16. Progesterone receptor membrane component 1 leads to erlotinib resistance, initiating crosstalk of Wnt/β-catenin and NF-κB pathways, in lung adenocarcinoma cells.
Lin Y; Higashisaka K; Shintani T; Maki A; Hanamuro S; Haga Y; Maeda S; Tsujino H; Nagano K; Fujio Y; Tsutsumi Y
Sci Rep; 2020 Mar; 10(1):4748. PubMed ID: 32179851
[TBL] [Abstract][Full Text] [Related]
17. Predictive value of BRCA1, ERCC1, ATP7B, PKM2, TOPOI, TOPΟ-IIA, TOPOIIB and C-MYC genes in patients with small cell lung cancer (SCLC) who received first line therapy with cisplatin and etoposide.
Karachaliou N; Papadaki C; Lagoudaki E; Trypaki M; Sfakianaki M; Koutsopoulos A; Mavroudis D; Stathopoulos E; Georgoulias V; Souglakos J
PLoS One; 2013; 8(9):e74611. PubMed ID: 24058603
[TBL] [Abstract][Full Text] [Related]
18. Tepotinib plus gefitinib in patients with EGFR-mutant non-small-cell lung cancer with MET overexpression or MET amplification and acquired resistance to previous EGFR inhibitor (INSIGHT study): an open-label, phase 1b/2, multicentre, randomised trial.
Wu YL; Cheng Y; Zhou J; Lu S; Zhang Y; Zhao J; Kim DW; Soo RA; Kim SW; Pan H; Chen YM; Chian CF; Liu X; Tan DSW; Bruns R; Straub J; Johne A; Scheele J; Park K; Yang JC;
Lancet Respir Med; 2020 Nov; 8(11):1132-1143. PubMed ID: 32479794
[TBL] [Abstract][Full Text] [Related]
19. [Association between the epidermal growth receptor status and the efficacy of
first-line chemotherapy in patients with advanced non-small cell lung cancer].
Qin N; Zhang Q; Wang J; Zhang H; Gu Y; Yang X; Li X; Lv J; Wu Y; Nong J; Zhang X; Zhang S
Zhongguo Fei Ai Za Zhi; 2015 Mar; 18(3):131-7. PubMed ID: 25800568
[TBL] [Abstract][Full Text] [Related]
20. Association of EGFR mutation or ALK rearrangement with expression of DNA repair and synthesis genes in never-smoker women with pulmonary adenocarcinoma.
Ren S; Chen X; Kuang P; Zheng L; Su C; Li J; Li B; Wang Y; Liu L; Hu Q; Zhang J; Tang L; Li X; Zhou C; Schmid-Bindert G
Cancer; 2012 Nov; 118(22):5588-94. PubMed ID: 22569898
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
